Phase I Oncology Drug Development
Timothy A. Yap (u. a.)
Sold by preigu, Osnabrück, Germany
AbeBooks Seller since 5 August 2024
New - Soft cover
Condition: New
Ships from Germany to U.S.A.
Quantity: 5 available
Add to basketSold by preigu, Osnabrück, Germany
AbeBooks Seller since 5 August 2024
Condition: New
Quantity: 5 available
Add to basketPhase I Oncology Drug Development | Timothy A. Yap (u. a.) | Taschenbuch | x | Englisch | 2021 | Springer | EAN 9783030476847 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Seller Inventory # 120488499
This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies.
The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. Theauthors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation.
This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.
Dr Timothy A. Yap MBBS PhD FRCP: Dr Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr Yap was a Clinician Scientist at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden Hospital in London, United Kingdom.
Dr Yap gained his BSc degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London and was awarded the Huggett Memorial Prize. He went on to attain a medical degree from Imperial College London, before completing general medical training in Oxford. Dr Yap undertook a Clinical Fellowship in the Phase I Drug Development Unit at the Royal Marsden Hospital, before completing a PhD in Molecular Pharmacology in the Division of Cancer Therapeutics at the Institute of Cancer Research under a Cancer Research UK Fellowship. His PhD laboratory research focused on the preclinical and clinical development of AKT inhibitors, and development of associated biomarkers.
Dr Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR and PARP inhibitors, as well as the development of novel immunotherapuetics.
Dr Jordi Rodon MD PhD: Dr Jordi Rodón specializes in early drug development, biomarker discovery, personalized cancer medicine, and neuro-oncology. He is now at MD Anderson’s Investigational Cancer Therapeutics department after moving from Barcelona, where he has been the director and clinical head of the Research Unit for Molecular Therapy of Cancer at the Vall d’Hebron University Hospital in Barcelona, Spain. Within this unit, he served as clinical head of the Early Clinical Drug Development Group, which aims to develop best-in-class targeted therapies, determine patient populations most likely to benefit using personalized molecular characterization, and identify biomarkers of response. At Vall d’Hebron University Hospital he was also in charge of the Neuroncology program, building it in collaboration with the Phase I Unit, the multidisciplinary clinic and the Gene Expression and Cancer Laboratory leaded by Joan Seoane.
Dr Rodón earned his medical and doctoral degrees at the Universitat Autònoma de Barcelona, and completed a doctorate the Universitat de Barcelona. He spent two years at the Advanced Drug Development program at the Institute for Drug Development (IDD) in San Antonio, Texas and completed his training in drug development at MD Anderson Cancer Center as a senior clinical research fellow. During this time at MDACC, Dr Rodón also completed an internship at the Kleberg Center for Molecular Markers under the direction of Dr. Gordon Mills.
Over the course of his career, Dr Rodón has been the principal or co-principal investigator on over 30 early phase clinical trials focusing on a range of advanced solid malignancies, partnering with leaders in industry including Novartis, Merck, Eli Lilly, Genentech, Sanofi, and others. With this, hehas contributed to about 60 peer-reviewed publications detailing both trial results and basic research findings. Dr. Rodón’s most significant contributions to the field include the development of PI3K, FGFR and TGFbeta inhibitors, pilot studies in Precision/Personalized Cancer Medicine and multiple translational collaborations in those fields.
David S Hong, M.D. is Deputy Chair at the department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. His research interests include Phase I studies Drug development and the molecular basis of cancer. He studied medicine at the Albert Einstein College of Medicine and specialised in oncology at Yale University.
"About this title" may belong to another edition of this title.
Standard Business Terms and customer information / data protection declaration / battery disposal
I. Standard business terms
§ 1 Basic provisions
(1) The following terms and conditions of business apply for all contracts concluded with us as the supplier (preigu GmbH & Co. KG) via the websites AbeBooks and/or ZVAB. Unless otherwise agreed, the inclusion of your own terms and conditions is explicitly rejected.
(2) A ?consumer' in the sense of the following regulations is every natural person who ...
Instructions for revocation
Revocation right for consumers
(A ‘consumer' is any natural person who concludes a legal transaction which, to an overwhelming extent, cannot be attributed to either his commercial or independent professional activities.)
Instructions for revocation
Revocation right
You have the right to revoke this contract within 14 days without specifying any reasons.
The revocation period is 14 days with effect from the day,
on which you or a third party nominated by you, which is not the carrier, had taken possession of the products, provided you had ordered one or more products within the scope of a standard order and this/these product/products is/are delivered uniformly;
on which you or a third party nominated by you, which is not the carrier, had taken possession of the last product, provided you had ordered several products within the scope of a standard order and these products are delivered separately;
on which you or a third party nominated by you, which is not the carrier, had taken possession of the last part delivery or the last unit, provided you had ordered a product, which is delivered in several part deliveries or units;
To exercise your right of withdrawal, you must inform us (preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, Telephone number: +49 (0) 541 / 580 72 84, E-Mail address: mail@preigu.de) by means of a clear declaration (e.g. a letter sent by post, or an e-mail) of your decision to withdraw from this contract. You can use the attached model withdrawal form for this purpose, which is, however, not mandatory.
In order to safeguard the revocation period, it is sufficient that you send the notification about the exercise of the revocation right before the expiry of the revocation period.
Consequences of the revocation
If you revoke this contract, we shall repay all the payments, which we received from you, including the delivery costs (with the exception of additional costs, which arise from that fact that you selected a form of delivery other than the most reasonable standard delivery offered by us), immediately and at the latest within 14 days from the day on which we received the notification about the revocation of this contract from you. We use the same means of payment, which you had originally used during the original transaction, for this repayment unless expressly agreed otherwise with you; you will not be charged any fees owing to this repayment.
We can refuse the repayment until the products are returned to us or until you have furnished evidence that you have sent the products back to us, depending on whichever is earlier.
You must return or transfer the products to us immediately and, in any case, at the latest within 14 days with effect from the day on which you inform us of the revocation of this contract. The deadline is maintained if you send the products before the expiry of the 14 day deadline.
You bear the direct costs for returning the products.
You must pay for any depreciation of the products only if this depreciation can be attributed to any handling with you that was not necessary for checking the condition, features and functionality of the products.
Criteria for exclusion or expiry
The revocation right is not available for contracts
for delivery of products, which are not prefabricated and for whose manufacturing an individual selection or stipulation by the consumer is important or which are clearly tailored to the personal requirements of the consumer;
for delivery of products, which can spoil quickly or whose use-by date would be exceeded quickly;
for delivery of alcoholic drinks, whose price was agreed at the time of concluding the contract, which however can be delivered 30 days after the conclusion of the contract at the earliest and whose current value depends on the fluctuations in the market, on which the entrepreneur has no influence;
for delivery of newspapers, periodicals or magazines with the exception of subscription contracts. The revocation right expires prematurely in case of contracts
for delivery of sealed products, which are not suitable for return for reasons of health protection or hygiene if their seal has been removed after the delivery;
for delivery of products if they have been mixed inseparably with other goods after the delivery, owing to their condition;
for delivery of sound or video recording or computer software in a sealed package if the seal has been removed after the delivery.
Specimen - revocation form
(If you wish to revoke the contract, please fill up this form and send it back to us.)
To preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, Email address: mail@preigu.de :
I/we () herewith revoke the contract concluded by me/ us () regarding the purchase of the following products ()/
the provision of the following service ()
Ordered on ()/ received on ()
Name of the consumer(s)
Address of the consumer(s)
Signature of the consumer(s) (only in case of a notification on paper)
Date
(*) Cross out the incorrect option.
| Order quantity | 60 to 60 business days | 60 to 60 business days |
|---|---|---|
| First item | £ 60.48 | £ 60.48 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.